A Trial of the Senolytic Fisetin as a Treatment for Older SARS-CoV-2 Patients

We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. Link: https://doi.org/10.1111/jgs.17416
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs